Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Praecis and Schering AG enter Plenaxis commercialization agreement

April 30, 2004

European approval for Velcade in multiple myeloma

April 30, 2004

New positive opinion for Herceptin plus Taxotere in E.U.

April 29, 2004

EntreMed completes phase I trial with reformulated Panzem

April 29, 2004

Allergan to withdraw PEP-005 INDs, resubmission planned

April 29, 2004

Cellular Genomics patent covers new protein kinase modulators

April 29, 2004

Two novel series of CDK inhibitors presented by Schering-Plough and Pharmacopeia

April 29, 2004

NF-kappaB inhibitor DHMEQ as treatment option for advanced urological cancer

April 29, 2004

Novel proteasome inhibitor ER807446 demonstrates antitumor activity especially against large tumors

April 29, 2004

ViRexx Medical receives grant to fund phase I trial of Occlusin

April 28, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...